交易中 04-01 10:49:42 美东时间
+0.420
+2.43%
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
Oppenheimer analyst Ian Zaffino initiates coverage on Lindblad Expeditions (NASDAQ:LIND) with a Outperform rating and announces Price Target of $25.
03-16 20:15
今日重点评级关注:巴克莱:维持C4 Therapeutics"超配"评级,目标价从5美元升至7美元;富国银行:维持Agilon Health"超配"评级,目标价从1美元升至1.5美元
03-02 14:08
Benchmark analyst Michael Albanese maintains Lindblad Expeditions (NASDAQ:LIND) with a Buy and raises the price target from $18 to $25.
02-28 01:34
Lindblad Expeditions Q4 adjusted EBITDA beats expectations Overview Expedition travel provider's Q4 adjusted EBITDA beat analyst expectations Company's 2025 revenue grew 20% yr/yr to $771 mln Company refinanced long-term debt, extending maturity to 2030 Outlook Company expects 2026 tour revenues of
02-26 20:46
The Q4 earnings report for Lindblad Expeditions (NASDAQ:LIND) was released on T...
02-26 20:34
The Company's current expectations for the full year 2026 are as follows:Tour revenues of $800 - $850 millionAdjusted EBITDA of $130 - $140 million
02-26 20:33
Lindblad Expeditions (NASDAQ:LIND) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.32) by 40.63 percent. This is a 6.25 percent increase over losses of $(0.48) per share
02-26 20:32
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Lindblad Expeditions Holdings (NASDAQ: LIND) said on Tuesday it has exercised its right to mandatorily convert all outstanding shares of its 6.0% Series A convertible preferred stock into common stock...
01-20 21:39